Lennham Pharmaceuticals Announces Issuance of U.S. Patent Covering Methods of Administering Psilocybin and Psilocin
- Patent claims cover methods of administering psilocybin and psilocin to patients having reduced monoamine oxidase A activity
- New patent expires in 2041
- Given implications to patient safety, Lennham’s discoveries are likely to cover information in the label of any future psilocybin- or psilocin-based product or structurally related compounds
May 31, 2022 10:03 AM Eastern Daylight Time
CONCORD, Mass.–(BUSINESS WIRE)–Lennham Pharmaceuticals, a start-up focused on the creative use of deuterium chemistry to improve the metabolic and pharmacological profile of existing compounds, today announced that the United States Patent & Trademark Office (USPTO) issued U.S. Patent No. 11,344,564 with an expiration date of December 2041. This patent covers methods of treating neurological or psychiatric disorders in patients having reduced monoamine oxidase A (MAO-A) activity by administering a below-normal dose of psilocybin or psilocin.
“Lennham has discovered that certain patient populations have traits that may affect the metabolism and, consequently, the pharmacological effects of psilocybin and its active metabolite, psilocin, at the site of action in the CNS”Tweet this
“Lennham has discovered that certain patient populations have traits that may affect the metabolism and, consequently, the pharmacological effects of psilocybin and its active metabolite, psilocin, at the site of action in the CNS,” said Bradford C. Sippy, Founder of Lennham. “Although glucoronidation is psilocin’s primary metabolic route systemically, metabolism by MAO-A plays a much greater role at the site of action. The use of psilocybin or psilocin in patients having an MAO-A deficiency requires a new approach to administration of those products. Our newly issued patent covers methods of using psilocybin and psilocin in these patient populations, which we believe will be incorporated into the eventual labeling for any psilocybin- or psilocin-based product.”
About Psilocybin
Psilocybin is a well-known, naturally occurring chemical in certain mushrooms that is known to produce hallucinogenic (psychedelic) effects in humans when consumed. It is currently being evaluated as a potential treatment for treatment-resistant depression1 and major depressive disorder, among other diseases and conditions.
About Lennham Pharmaceuticals, Inc.
Lennham is a privately held, life sciences company focused on the creative application of deuterium chemistry to highly utilized and well-characterized compounds. Founded in 2019, Lennham’s unique approach to deuteration has enabled it to rapidly develop a pipeline of product candidates, including deuterium-enriched forms of psilocybin, caffeine, and testosterone.
For more information please visit www.lennham.com or contact info@lennham.com.
References
- Carhart-Harris R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021 Apr 15;384(15):1402-1411
Contacts
Media:
Corey MacGregor
Chief Business Officer
Lennham Pharmaceuticals
Corey.macgregor@lennham.com
(978) 254-3201